- NCIt
- C8964
Loading cancer entity…
Loading cancer entity…
Clinical trials
25 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03069469 | Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor | active not recruiting | Phase 1 / Phase 2 | 120 | Deciphera Pharmaceuticals, LLCINDUSTRY | 9 | Jun 25, 2026 | clinicaltrials |
| NCT04192344 | A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor | recruiting | Phase 1 | 276 | Abbisko Therapeutics Co, LtdINDUSTRY | 2 | Mar 19, 2026 | clinicaltrials |
| NCT02471716 | Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor(FPA008-002) | completed | Phase 1 / Phase 2 | 66 | Five Prime Therapeutics, Inc.INDUSTRY | 6 | Aug 31, 2021 | clinicaltrials |
| NCT01804530 |
Data updated 22 days agoSource updated Jun 25, 2026source: clinicaltrials
| Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors |
| terminated |
| Phase 1 |
| 59 |
| PlexxikonINDUSTRY |
| 1 |
| Aug 2, 2018 |
| clinicaltrials |
| NCT02673736 | A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor | terminated | Phase 1 | 11 | PlexxikonINDUSTRY | 1 | Aug 2, 2018 | clinicaltrials |